{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T22:40:10Z","timestamp":1769812810554,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05346-w","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:42:37Z","timestamp":1766515357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of combining targeted therapies or chemotherapy with stereotactic radiosurgery (SRS) on the prognosis of patients with brain metastases from non-small cell lung cancer (NSCLC)"],"prefix":"10.1007","volume":"176","author":[{"given":"Guy N.","family":"Ron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan G.","family":"Ron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halit","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyal","family":"Fening","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shlomit","family":"Yust-Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Amiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosef","family":"Laviv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin W.","family":"Corn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew A.","family":"Kanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"11","key":"5346_CR1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","volume":"19","author":"DN Cagney","year":"2017","unstructured":"Cagney DN, Martin AM, Catalano PJ et al (2017) Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol 19(11):1511\u20131521. https:\/\/doi.org\/10.1093\/neuonc\/nox077","journal-title":"Neuro Oncol"},{"issue":"14","key":"5346_CR2","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system. J Clin Oncol 22(14):2865\u20132872. https:\/\/doi.org\/10.1200\/JCO.2004.12.149","journal-title":"J Clin Oncol"},{"key":"5346_CR3","doi-asserted-by":"publisher","unstructured":"Mehta MP, Rodrigus P, Terhaard CHJ et al (2003) Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21(13). https:\/\/doi.org\/10.1200\/JCO.2003.12.122","DOI":"10.1200\/JCO.2003.12.122"},{"key":"5346_CR4","doi-asserted-by":"publisher","unstructured":"Lutterbach J, Bartelt S, Ostertag C (2002) Long-term survival in patients with brain metastases. J Cancer Res Clin Oncol 128(8). https:\/\/doi.org\/10.1007\/s00432-002-0354-1","DOI":"10.1007\/s00432-002-0354-1"},{"key":"5346_CR5","doi-asserted-by":"publisher","unstructured":"Xue J, Kubicek GJ, Grimm J et al (2014) Biological implications of whole-brain radiotherapy versus stereotactic radiosurgery of multiple brain metastases. J Neurosurg 121. https:\/\/doi.org\/10.3171\/2014.7.GKS141229","DOI":"10.3171\/2014.7.GKS141229"},{"key":"5346_CR6","doi-asserted-by":"publisher","unstructured":"Franchino F, Rud\u00e0 R, Soffietti R (2018) Mechanisms and therapy for cancer metastasis to the brain. Front Oncol Front Media S A 8(MAY). https:\/\/doi.org\/10.3389\/fonc.2018.00161","DOI":"10.3389\/fonc.2018.00161"},{"key":"5346_CR7","doi-asserted-by":"publisher","unstructured":"Soliman H, Das S, Larson DA, Sahgal A (2016) Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases. Oncotarget 7(11). https:\/\/doi.org\/10.18632\/oncotarget.7131","DOI":"10.18632\/oncotarget.7131"},{"key":"5346_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.canrad.2020.06.013","volume":"24","author":"F Dhermain","year":"2020","unstructured":"Dhermain F, No\u00ebl G, Antoni D, Tallet A (2020) Role of radiation therapy in brain metastases management. Cancer\/Radiotherapie 24:6\u20137. https:\/\/doi.org\/10.1016\/j.canrad.2020.06.013","journal-title":"Cancer\/Radiotherapie"},{"key":"5346_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/nature14432","author":"A Louveau","year":"2015","unstructured":"Louveau A, Smirnov I, Keyes TJ et al (2015) Structural and functional features of central nervous system lymphatic vessels. Nat Published Online. https:\/\/doi.org\/10.1038\/nature14432","journal-title":"Nat Published Online"},{"key":"5346_CR10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5696","author":"PN Harter","year":"2015","unstructured":"Harter PN, Bernatz S, Scholz A et al (2015) Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1\/PD-L1 immune checkpoints in human brain metastases. Oncotarget Published Online. https:\/\/doi.org\/10.18632\/oncotarget.5696","journal-title":"Oncotarget Published Online"},{"key":"5346_CR11","doi-asserted-by":"publisher","unstructured":"Park SJ, Kim HT, Lee DH et al (2012) Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77(3). https:\/\/doi.org\/10.1016\/j.lungcan.2012.05.092","DOI":"10.1016\/j.lungcan.2012.05.092"},{"key":"5346_CR12","doi-asserted-by":"publisher","unstructured":"Lazaro T, Brastianos PK (2017) Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. CNS Oncol 6(2). https:\/\/doi.org\/10.2217\/cns-2016-0038","DOI":"10.2217\/cns-2016-0038"},{"issue":"5","key":"5346_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","volume":"40","author":"MA Vogelbaum","year":"2022","unstructured":"Vogelbaum MA, Brown PD, Messersmith H et al (2022) Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40(5):492\u2013516. https:\/\/doi.org\/10.1200\/JCO.21.02314","journal-title":"J Clin Oncol"},{"key":"5346_CR14","doi-asserted-by":"publisher","unstructured":"Hochmair M (2018) Medical treatment options for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer suffering from brain metastases and\/or leptomeningeal disease. Target Oncol 13(3). https:\/\/doi.org\/10.1007\/s11523-018-0566-1","DOI":"10.1007\/s11523-018-0566-1"},{"issue":"62","key":"5346_CR15","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.18632\/oncotarget.27328","volume":"10","author":"RH Han","year":"2019","unstructured":"Han RH, Dunn GP, Chheda MG, Kim AH (2019) The impact of systemic precision medicine and immunotherapy treatments on brain metastases. Oncotarget 10(62):6739\u20136753. https:\/\/doi.org\/10.18632\/oncotarget.27328","journal-title":"Oncotarget"},{"key":"5346_CR16","doi-asserted-by":"publisher","unstructured":"Aquilanti E, Brastianos PK (2020) Immune checkpoint inhibitors for brain metastases: a primer for neurosurgeons. Neurosurgery 87(3). https:\/\/doi.org\/10.1093\/neuros\/nyaa095","DOI":"10.1093\/neuros\/nyaa095"},{"key":"5346_CR17","doi-asserted-by":"publisher","unstructured":"Dunn GP, Okada H (2015) Principles of immunology and its nuances in the central nervous system. Neuro Oncol 17. https:\/\/doi.org\/10.1093\/neuonc\/nov175","DOI":"10.1093\/neuonc\/nov175"},{"issue":"1","key":"5346_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41568-019-0220-y","volume":"20","author":"A Boire","year":"2020","unstructured":"Boire A, Brastianos PK, Garzia L, Valiente M (2020) Brain metastasis. Nat Rev Cancer 20(1):4\u201311. https:\/\/doi.org\/10.1038\/s41568-019-0220-y","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"5346_CR19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jtho.2023.03.004","volume":"18","author":"F Acker","year":"2023","unstructured":"Acker F, Althoff FC, Sebastian M (2023) Systemic treatment for brain metastases in NSCLC: a new chapter. J Thorac Oncol 18(6):678\u2013681. https:\/\/doi.org\/10.1016\/j.jtho.2023.03.004","journal-title":"J Thorac Oncol"},{"issue":"6","key":"5346_CR20","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1200\/JCO.21.01715","volume":"40","author":"DCC Tsui","year":"2022","unstructured":"Tsui DCC, Camidge DR, Rusthoven CG (2022) Managing central nervous system spread of lung cancer: the state of the Art. J Clin Oncol 40(6):642\u2013660. https:\/\/doi.org\/10.1200\/JCO.21.01715","journal-title":"J Clin Oncol"},{"issue":"7","key":"5346_CR21","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"S Goldberg","year":"2016","unstructured":"Goldberg S, Gettinger S, Mahajan A et al (2016) A phase II trial of pembrolizumab for patients with melanoma or non-small cell lung cancer and untreated brain metastases. Lancet Oncol 17(7):976\u2013983. https:\/\/doi.org\/10.1016\/S1470-2045(16)30053-5","journal-title":"Lancet Oncol"},{"key":"5346_CR22","doi-asserted-by":"publisher","unstructured":"Balasubramanian SK, Sharma M, Venur VA et al (2020) Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis. Neuro Oncol 22(2). https:\/\/doi.org\/10.1093\/neuonc\/noz155","DOI":"10.1093\/neuonc\/noz155"},{"key":"5346_CR23","doi-asserted-by":"publisher","unstructured":"Kim HJ, Kim WS, Kwon DH, Cho YH, Choi CM (2015) Effects of an epithelial growth factor receptor-tyrosine kinase inhibitor add-on in stereotactic radiosurgery for brain metastases originating from non-small-cell lung cancer. J Korean Neurosurg Soc 58(3). https:\/\/doi.org\/10.3340\/jkns.2015.58.3.205","DOI":"10.3340\/jkns.2015.58.3.205"},{"key":"5346_CR24","doi-asserted-by":"publisher","unstructured":"Tsakonas G, Lewensohn R, Botling J et al (2020) An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non\u2013small-cell lung cancer. Eur J Cancer 132. https:\/\/doi.org\/10.1016\/j.ejca.2020.03.014","DOI":"10.1016\/j.ejca.2020.03.014"},{"key":"5346_CR25","doi-asserted-by":"publisher","unstructured":"Shaw E, Kline R, Gillin M et al (1993) Radiation therapy oncology group: radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys 27(5). https:\/\/doi.org\/10.1016\/0360-3016(93)90548-A","DOI":"10.1016\/0360-3016(93)90548-A"},{"key":"5346_CR26","doi-asserted-by":"publisher","unstructured":"Patchell RA, Tibbs PA, Regine WF et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 280(17). https:\/\/doi.org\/10.1001\/jama.280.17.1485","DOI":"10.1001\/jama.280.17.1485"},{"key":"5346_CR27","doi-asserted-by":"publisher","unstructured":"Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20(11). https:\/\/doi.org\/10.1038\/s41577-020-0306-5","DOI":"10.1038\/s41577-020-0306-5"},{"issue":"4","key":"5346_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s10147-014-0717-z","volume":"19","author":"CW Song","year":"2014","unstructured":"Song CW, Kim MS, Cho LC, Dusenbery K, Sperduto PW (2014) Radiobiological basis of SBRT and SRS. Int J Clin Oncol Springer-Verlag Tokyo 19(4):570\u2013578. https:\/\/doi.org\/10.1007\/s10147-014-0717-z","journal-title":"Int J Clin Oncol Springer-Verlag Tokyo"},{"key":"5346_CR29","doi-asserted-by":"publisher","unstructured":"Hu X, Yu H, Zheng Y et al (2020) Immune checkpoint inhibitors and survival outcomes in brain metastasis: a time series-based meta-analysis. Front Oncol 10. https:\/\/doi.org\/10.3389\/fonc.2020.564382","DOI":"10.3389\/fonc.2020.564382"},{"key":"5346_CR30","doi-asserted-by":"publisher","unstructured":"Engelhardt B, Vajkoczy P, Weller RO (2017) The movers and shapers in immune privilege of the CNS. Nat Immunol 18(2). https:\/\/doi.org\/10.1038\/ni.3666","DOI":"10.1038\/ni.3666"},{"key":"5346_CR31","doi-asserted-by":"publisher","unstructured":"Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR -Mutated advanced non\u2013small-cell lung cancer. N Engl J Med 378(2). https:\/\/doi.org\/10.1056\/nejmoa1713137","DOI":"10.1056\/nejmoa1713137"},{"key":"5346_CR32","doi-asserted-by":"publisher","unstructured":"Yang JCH, Wu YL, Schuler M et al (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16(2). https:\/\/doi.org\/10.1016\/S1470-2045(14)71173-8","DOI":"10.1016\/S1470-2045(14)71173-8"},{"key":"5346_CR33","doi-asserted-by":"publisher","unstructured":"Kudo Y, Haymaker C, Zhang J et al (2019) Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann Oncol 30(9). https:\/\/doi.org\/10.1093\/annonc\/mdz207","DOI":"10.1093\/annonc\/mdz207"},{"key":"5346_CR34","doi-asserted-by":"publisher","unstructured":"Brastianos PK, Carter SL, Santagata S et al (2015) Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5(11). https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0369","DOI":"10.1158\/2159-8290.CD-15-0369"},{"key":"5346_CR35","doi-asserted-by":"publisher","unstructured":"Paik PK, Shen R, Won H et al (2016) Next-generation sequencing of stage IV squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain metastases. Cancer Discov 5(6). https:\/\/doi.org\/10.1158\/2159-8290.CD-14-1129","DOI":"10.1158\/2159-8290.CD-14-1129"},{"key":"5346_CR36","doi-asserted-by":"publisher","unstructured":"Lehrer EJ, Peterson J, Brown PD et al (2019) Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol 130. https:\/\/doi.org\/10.1016\/j.radonc.2018.08.025","DOI":"10.1016\/j.radonc.2018.08.025"},{"key":"5346_CR37","doi-asserted-by":"publisher","unstructured":"Shaverdian N, Lisberg AE, Bornazyan K et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18(7). https:\/\/doi.org\/10.1016\/S1470-2045(17)30380-7","DOI":"10.1016\/S1470-2045(17)30380-7"},{"key":"5346_CR38","doi-asserted-by":"publisher","unstructured":"Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Sci (1979) 348(6230). https:\/\/doi.org\/10.1126\/science.aaa4971","DOI":"10.1126\/science.aaa4971"},{"key":"5346_CR39","doi-asserted-by":"publisher","unstructured":"Blank C, Gajewski TF, Mackensen A (2005) Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 54(4). https:\/\/doi.org\/10.1007\/s00262-004-0593-x","DOI":"10.1007\/s00262-004-0593-x"},{"key":"5346_CR40","doi-asserted-by":"publisher","unstructured":"Finkelstein SE, Timmerman R, McBride WH, et al (2011) The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol. 2011. https:\/\/doi.org\/10.1155\/2011\/439752","DOI":"10.1155\/2011\/439752"},{"key":"5346_CR41","doi-asserted-by":"publisher","unstructured":"Van Vulpen M, Kal HB, Taphoorn MJB, El Sharouni SY (2002) Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep 9(4). https:\/\/doi.org\/10.3892\/or.9.4.683","DOI":"10.3892\/or.9.4.683"},{"key":"5346_CR42","doi-asserted-by":"publisher","unstructured":"Jiang T, Min W, Li Y, Yue Z, Wu C, Zhou C (2016) Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis. Cancer Med 5(6). https:\/\/doi.org\/10.1002\/cam4.673","DOI":"10.1002\/cam4.673"},{"key":"5346_CR43","doi-asserted-by":"publisher","unstructured":"Ahsan A (2016) Mechanisms of resistance to EGFR tyrosine kinase inhibitors and therapeutic approaches: an update. Adv Exp Med Biol 893. https:\/\/doi.org\/10.1007\/978-3-319-24223-1_7","DOI":"10.1007\/978-3-319-24223-1_7"},{"key":"5346_CR44","doi-asserted-by":"publisher","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell lung cancer. N Engl J Med 375(19). https:\/\/doi.org\/10.1056\/nejmoa1606774","DOI":"10.1056\/nejmoa1606774"},{"key":"5346_CR45","doi-asserted-by":"crossref","unstructured":"Myall NJ, Yu H, Soltys SG, Wakelee HA, Pollom E (2021) Neuro-oncology advances the era of targeted and immune therapies. 3:52\u201362","DOI":"10.1093\/noajnl\/vdab106"},{"key":"5346_CR46","doi-asserted-by":"publisher","unstructured":"Bowden G, Kano H, Caparosa E et al (2015) Gamma knife radiosurgery for the management of cerebral metastases from non-small cell lung cancer. J Neurosurg 122(4). https:\/\/doi.org\/10.3171\/2014.12.JNS141111","DOI":"10.3171\/2014.12.JNS141111"},{"issue":"3","key":"5346_CR47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11060-022-03981-1","volume":"157","author":"Z Wei","year":"2022","unstructured":"Wei Z, Niranjan A, Abou-Al-Shaar H, Deng H, Albano L, Lunsford LD (2022) A volume matched comparison of survival after radiosurgery in non-small cell lung cancer patients with one versus more than Twenty brain metastases. J Neurooncol 157(3):417\u2013423. https:\/\/doi.org\/10.1007\/s11060-022-03981-1","journal-title":"J Neurooncol"},{"issue":"3","key":"5346_CR48","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s11060-024-04749-5","volume":"169","author":"KL Cole","year":"2024","unstructured":"Cole KL, Earl ER, Findlay MC et al (2024) Assessing survival in non-small cell lung cancer brain metastases after stereotactic radiosurgery: before and after the start of the targetable mutation era. J Neurooncol 169(3):671\u2013681. https:\/\/doi.org\/10.1007\/s11060-024-04749-5","journal-title":"J Neurooncol"},{"key":"5346_CR49","doi-asserted-by":"publisher","unstructured":"Chen L, Douglass J, Kleinberg L et al (2018) Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in Non-Small cell lung Cancer, Melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys 100(4). https:\/\/doi.org\/10.1016\/j.ijrobp.2017.11.041","DOI":"10.1016\/j.ijrobp.2017.11.041"},{"key":"5346_CR50","doi-asserted-by":"publisher","unstructured":"Johung KL, Yeh N, Desai NB et al (2016) Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34(2). https:\/\/doi.org\/10.1200\/JCO.2015.62.0138","DOI":"10.1200\/JCO.2015.62.0138"},{"issue":"6","key":"5346_CR51","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","volume":"3","author":"PW Sperduto","year":"2017","unstructured":"Sperduto PW, Yang TJ, Beal K et al (2017) Estimating survival in patients with lung cancer and brain metastases an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol 3(6):827\u2013831. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3834","journal-title":"JAMA Oncol"},{"key":"5346_CR52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.7144","author":"WJ Magnuson","year":"2017","unstructured":"Magnuson WJ, Lester-Coll NH, Wu AJ et al (2017) Management of brain metastases in tyrosine kinase inhibitor-Na\u00efve epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol Published Online. https:\/\/doi.org\/10.1200\/JCO.2016.69.7144","journal-title":"J Clin Oncol Published Online"},{"key":"5346_CR53","doi-asserted-by":"publisher","unstructured":"Likhacheva A, Pinnix CC, Parikh NR et al (2013) Predictors of survival in contemporary practice after initial radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 85(3). https:\/\/doi.org\/10.1016\/j.ijrobp.2012.05.047","DOI":"10.1016\/j.ijrobp.2012.05.047"},{"key":"5346_CR54","doi-asserted-by":"publisher","unstructured":"Routman DM, Bian SX, Diao K et al (2018) The growing importance of lesion volume as a prognostic factor in patients with multiple brain metastases treated with stereotactic radiosurgery. Cancer Med 7(3). https:\/\/doi.org\/10.1002\/cam4.1352","DOI":"10.1002\/cam4.1352"},{"issue":"4","key":"5346_CR55","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/neuonc\/now184","volume":"19","author":"ER McTyre","year":"2017","unstructured":"McTyre ER, Johnson AG, Ruiz J et al (2017) Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy. Neuro Oncol 19(4):558\u2013566. https:\/\/doi.org\/10.1093\/neuonc\/now184","journal-title":"Neuro Oncol"},{"issue":"5","key":"5346_CR56","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jtho.2017.12.006","volume":"13","author":"TP Robin","year":"2018","unstructured":"Robin TP, Camidge DR, Stuhr K et al (2018) Excellent outcomes with radiosurgery for multiple brain metastases in ALK and EGFR driven Non\u2013Small cell lung cancer. J Thorac Oncol 13(5):715\u2013720. https:\/\/doi.org\/10.1016\/j.jtho.2017.12.006","journal-title":"J Thorac Oncol"},{"key":"5346_CR57","doi-asserted-by":"publisher","unstructured":"Park K, Tan EH, O\u2019Byrne K et al (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial. Lancet Oncol 17(5). https:\/\/doi.org\/10.1016\/S1470-2045(16)30033-X","DOI":"10.1016\/S1470-2045(16)30033-X"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05346-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05346-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05346-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:47:24Z","timestamp":1769773644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05346-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5346"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05346-w","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article has been revised: The last author's first affiliation has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local institutional review board (ethics approval number 0624-19-RMC). Due to the retrospective nature of the study, written informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}